宜宾纹眼线要多少钱(宜宾哪里割双眼皮正规医院) (今日更新中)

LOS ANGELES, June 5 (Xinhua) -- U.S. researchers have developed two new drugs that can prolong the lives of patients with advanced melanoma, it was announced on Sunday.Research on both drugs was presented at the on-going annual meeting of the American Society of Clinical Oncology in Chicago, according to HealthDay News.This is the first big news in years for treatment of melanoma, one of the deadliest forms of skin cancer and one that is notoriously difficult to treat, let alone cure, the report said.The first treatment, vemurafenib, inhibits a gene mutation harbored in half of all melanoma patients, but is not yet approved by the U.S. Food and Drug Administration.The other drug, Yervoy (ipilumumab), is an immune system therapy that won approval in March."The March FDA approval of ipilumumab (Yervoy) was the first new drug approval for melanoma in 13 years," said Tim Turnham, executive director of the Melanoma Research Foundation.The two drugs were developed by researchers at Memorial Sloan- Kettering Cancer Center in New York City, the report said."This is really a huge step toward personalized care in melanoma," Dr. Paul Chapman, lead author of the first study and the attending physician in the melanoma/sarcoma service at Memorial Sloan-Kettering, said in a statement. "This (vemurafenib) is the first successful melanoma treatment tailored to patients who carry a specific gene mutation in their tumor, and could eventually become one of only two drugs available that improves overall survival in advanced cancers.""Having two trials that show a benefit in survival in patients with melanoma, both of these in first-line settings -- we weren't here just a few years ago," said Dr. Stephen Hodi, director of the Melanoma Center at Dana Farber Cancer Institute in Boston. "These are huge, paradigm-shifting results for the field."In the vemurafenib trial, sponsored by the drug's makers, researchers randomly assigned 675 patients with advanced, inoperable melanoma to receive either the chemotherapy drug dacarbazine or vemurafenib. Vemurafenib targets the V600E mutation in the BRAF gene.At the three-month mark, patients taking vemurafenib were 63 percent less likely to die and 74 percent less likely to die or see their cancer return, compared to patients taking dacarbazine alone.Few patients had side effects in the vemurafenib group, although some did develop squamous cell carcinoma, a less dangerous form of skin cancer.This is the first drug that has been proven superior to chemotherapy in this group of hard-to-treat patients, the researchers said."There was such a substantial benefit that we recommended that patients cross over," Chapman said at a Sunday news briefing. "It' s unprecedented to report a trial this early. The median follow-up time was three months." Yet the differences between the two groups became evident almost immediately.Dr. Lynn Schuchter, co-moderator of the briefing and division chief of hematology-oncology at Abramson Cancer Center of the University of Pennsylvania in Philadelphia, said symptoms subsided in some patients almost immediately, enabling them to cut back on pain medication in just 72 hours."The median time to progression with dacarbazine was 1.6 months versus three months with vemurafenib, which is a huge difference," said Chapman.In the second study, about 500 patients were randomly picked to receive Yervoy plus dacarbazine or dacarbazine alone.Those taking both drugs lived a median of 11.2 months compared to 9.1 months for those taking dacarbazine alone. Time to recurrence of disease was about the same for both groups: 2.8 months and 2.6 months, respectively.Almost half of those taking the combination therapy were alive after one year, compared to 36.3 percent in the other group. After two years, the rates were 28.5 percent and 17.9 percent, respectively.By three years out, 20.8 percent of those in the combination group were alive compared with 12.2 percent of those taking chemotherapy alone.This is the first study to combine chemotherapy and immunotherapy both safely and effectively.A study to test vemurafenib in combination with Yervoy has already begun, according to HealthDay News.

LOS ANGELES, June 9 (Xinhua) -- The edge of our solar system may not be smooth, but filled with a turbulent sea of magnetic bubbles approximately 100 million miles (160 million kilometers) wide, NASA's Jet Propulsion Laboratory (JPL) said on Thursday.The finding was based on observations from NASA's Voyager spacecraft, humanity's farthest deep space sentinels, said JPL in Pasadena, Los Angeles.While using a new computer model to analyze Voyager data, scientists found the sun's distant magnetic field is made up of bubbles which are created when magnetic field lines reorganize, said JPL.The new model suggests the field lines are broken up into self- contained structures disconnected from the solar magnetic field, according to JPL."The sun's magnetic field extends all the way to the edge of the solar system," said astronomer Merav Opher of Boston University. "Because the sun spins, its magnetic field becomes twisted and wrinkled, a bit like a ballerina's skirt. Far, far away from the sun, where the Voyagers are, the folds of the skirt bunch up."Like Earth, our sun has a magnetic field with a north pole and a south pole. The field lines are stretched outward by the solar wind, a stream of charged particles emanating from the star that interacts with material expelled from others in our corner of the Milky Way galaxy.Understanding the structure of the sun's magnetic field will allow scientists to explain how galactic cosmic rays enter our solar system and help define how the star interacts with the rest of the galaxy.The Voyager spacecraft, more than nine billion miles (14 billion kilometers) away from Earth, are traveling in a boundary region. In that area, the solar wind and magnetic field are affected by material expelled from other stars in our corner of the Milky Way galaxy.Launched in 1977, the Voyager twin spacecraft have been on a 33- year journey. They are en route to reach the edge of interstellar space. JPL built the spacecraft and continues to operate them.

MOSCOW, Aug. 7 (Xinhua) -- A state of emergency has been imposed in a district in the Krasnodar Region in south Russia amid an out break of the African swine fever, the regional emergencies center said on Sunday.The emergencies center told local reporters that the African swine fever virus (ASFV) was found in a private farm where 15 pigs died of the disease, but the source of the infection is still unclear.Local authorities said some 12,000 pigs in and around the Krylovskaya village, some three km away from the private farm, are being culled, 50 of which have already died of the ASFV in recent days.In April, the regional emergencies has temporarily declared a state of emergency in the Labinsky district in the region, as the ASFV was found at a livestock farm. 85 pigs were culled at the farm.

来源：资阳报